Long-term safety of icotinib in patients with non-small cell lung cancer: a retrospective, real-world study.

Abstract

BACKGROUND:

Lung cancer is a global health problem with a high mortality, and the development of target therapy has led to a revolution in the treatment of lung cancer in recent years. Favorable efficacy and safety of icotinib have been demonstrated in patients with non-small cell lung cancer (NSCLC). Currently, minimal data are available to describe the long-term safety of icotinib in NSCLC patients.

METHODS:

We reviewed the safety data from 1,321 advanced NSCLC patients who were treated with icotinib. The primary endpoint was the long-term safety, defined as any adverse drug reactions (ADRs) occurred after 6 months of icotinib administration.

RESULTS:

Fewer ADRs were noticed over 6 month administration of icotinib than within 6 months in overall population (24.3% vs. 65.4%), and elderly patients (23.6% vs. 66.9%). The majority of ADRs were grade 1-2 in severity over 6 month exposure of icotinib in overall population as well as elderly patients. In overall population, the most common ADRs of icotinib during long-term use were rash (16.4%) and diarrhea (5.3%), while the incidences were 31.8% and 13.2% in the induction period, respectively. In elderly population, the most common ADRs of icotinib during long-term use were rash (15.7%) and diarrhea (4.7%), while the incidences were 27.8% and 14.9% in the induction period, respectively, and more inching was observed in the induction period as compared with long term use (6.3% vs. 0.3%).

CONCLUSIONS:

There was an evidence of decreased frequency of icotinib-induced ADRs over time, and icotinib was well-tolerated in elderly NSCLC patients.

• Authors: Wen Zhang, Yiping Zhang, Qiong Zhao, Xiguang Liu, Likun Chen, Hongming Pan, Yuping Li, You Lu, Jianjin Huang, Zhe Zhang, Kaiqi Du, Suning Zhang, Tao Li, Liqin Lu, Guangmao Yu, Yang Wang, Xiaobin Yuan, Min Yang, Yongbin Ma, Fenlai Tan
• Journal: Journal of thoracic disease (J Thorac Dis) Vol. 12 Issue 3 Pg. 639-650 (Mar 2020) ISSN: 2072-1439 [Print] China
• PMID: 32274129 (Publication Type: Journal Article)
• Copyright: 2020 Journal of Thoracic Disease. All rights reserved.